A new Cambridge, Mass.-based startup, Thrive Earlier Detection (“Thrive” for short), has raised $110 million to develop a much-watched blood test that aims to detect cancer when it is still soon enough to remove it.

The company, whose existence STAT first reported on May 8, is entering a crowded field flooded with money. Grail, based in San Francisco, has raised $1.5 billion on a similar effort. According to Pitchbook, Grail is valued at $3.1 billion, and it will present data at cancer meeting this weekend. Other companies, including Guardant and Exact Sciences (one of Thrive’s investors) have expressed interest in the field of cancer detection via blood test, known as liquid biopsy.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy